NVCT (Nuvectis Pharma) Loans Receivable: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVCT Nuvectis Pharma Inc NVCT
26 GF Score
Price $19.14
! 1 Warning Sign
View Full Analysis

What is Nuvectis Pharma Loans Receivable?

Nuvectis Pharma NVCT +2.68% 26 Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates NVCT with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Nuvectis Pharma's Loans Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Nuvectis Pharma Loans Receivable Related Terms

Nuvectis Pharma Loans Receivable Historical Data

* Premium members only.

The historical data trend for Nuvectis Pharma's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvectis Pharma Loans Receivable Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nuvectis Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NVCT
26GF Score
Nuvectis Pharma Inc NVCT
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuvectis Pharma Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Nuvectis Pharma (NVCT) has a Loans Receivable of $0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Nuvectis Pharma and its competitors.
Is Nuvectis Pharma's Loans Receivable too high?
Nuvectis Pharma's current Loans Receivable is $0.00 Mil. Overall, Nuvectis Pharma has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Nuvectis Pharma's Loans Receivable compare to AURA and OCS?
Nuvectis Pharma's Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Nuvectis Pharma and its competitors. Nuvectis Pharma's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvectis Pharma stock overvalued right now?
Nuvectis Pharma (NVCT) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Nuvectis Pharma's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Nuvectis Pharma (NVCT), the current Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvectis Pharma Business Description

Address 1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
26GF Score

Get the complete analysis for NVCT

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.14
Price